Although a genetic basis for clinical response to CTLA-4 inhibition in melanoma has recently been suggested16, so far few studies have suggested a tumour-cell autonomous basis for response to PD-1/PD-L1 monoclonal antibodies. The gene discussed is CTLA4; the disease is melanoma.